Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,877,331
+645,331 (52.38%)
At close: Oct 30, 2025
Samsung Biologics Revenue
Samsung Biologics had revenue of 1.29T KRW in the quarter ending June 30, 2025, with 11.50% growth. This brings the company's revenue in the last twelve months to 5.03T, up 19.48% year-over-year. In the year 2024, Samsung Biologics had annual revenue of 4.55T with 23.08% growth.
Revenue (ttm)
5.03T
Revenue Growth
+19.48%
P/S Ratio
17.27
Revenue / Employee
996.97M
Employees
4,770
Market Cap
86.90T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.55T | 852.73B | 23.08% |
| Dec 31, 2023 | 3.69T | 693.29B | 23.10% |
| Dec 31, 2022 | 3.00T | 1.43T | 91.41% |
| Dec 31, 2021 | 1.57T | 403.23B | 34.62% |
| Dec 31, 2020 | 1.16T | 463.19B | 66.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |
Samsung Biologics News
- 5 weeks ago - Korean Stock Market Declines Amid Trade Uncertainty; Samsung Biologics (SSNLF) Drops - GuruFocus
- 5 weeks ago - Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal - The Times of India